ABSTRACT
Objectives The rapid integration of artificial intelligence (AI) in healthcare requires robust legal safeguards to ensure safety, privacy, and non-discrimination, crucial for maintaining trust. Yet, unaddressed differences in disciplinary perspectives and priorities risks impeding effective reform. This study uncovers convergences and divergences in disciplinary comprehension, prioritization, and proposed solutions to legal issues with health-AI, providing law and policymaking guidance.
Methods Employing a scoping review methodology, we searched MEDLINE® (Ovid), EMBASE (Ovid), HeinOnline Law Journal Library, Index to Foreign Legal Periodicals (HeinOnline), Index to Legal Periodicals and Books (EBSCOhost), Web of Science (Core Collection), Scopus, and IEEE Xplore, identifying legal issue discussions published, in English or French, from January 2012 to July 2021. Of 18,168 screened studies, 432 were included for data extraction and analysis. We mapped the legal concerns and solutions discussed by authors in medicine, law, nursing, pharmacy, other healthcare professions, public health, computer science, and engineering, revealing where they agree and disagree in their understanding, prioritization, and response to legal concerns.
Results Critical disciplinary differences were evident in both the frequency and nature of discussions of legal issues and potential solutions. Notably, innovators in computer science and engineering exhibited minimal engagement with legal issues. Authors in law and medicine frequently contributed but prioritized different legal issues and proposed different solutions.
Discussion and Conclusion Differing perspectives regarding law reform priorities and solutions jeopardize the progress of health-AI development. We need inclusive, interdisciplinary dialogues concerning the risks and trade-offs associated with various solutions to ensure optimal law and policy reform.
What is already known on this topic There has been no systematic examination of the multidisciplinary literature discussing legal challenges posed by health-AI. Prior efforts have addressed ethical concerns or limited subsets of legal issues or technologies, and therefore do not establish the comprehensive groundwork essential for fostering meaningful cross-disciplinary dialogue on health-AI regulation.
What this study adds Our study uncovers a shared interdisciplinary apprehension regarding the effective regulation of health-AI. However, distinct stakeholders such as physicians, innovators, and legal scholars hold divergent perspectives on these issues and their relative significance. Notably, certain critical voices, such as within discussions around informed consent, are conspicuously absent, hindering the prospects of effective reform.
How this study might affect research, practice, or policy The findings underscore the imperative for governments to facilitate inclusive dialogue and reconcile disparate disciplinary viewpoints. Effective regulation is pivotal in ensuring the safe and responsible deployment of health-AI for the public good. This study presents essential entry points for the much-needed discourse on this challenge facing governments around the world.
Competing Interest Statement
The authors have declared no competing interest.
Clinical Protocols
https://systematicreviewsjournal.biomedcentral.com/articles/10.1186/s13643-022-01939-y
Funding Statement
This study was funded by the Canadian Institutes of Health Research, the Hospital for Sick Children Research Institute, and the Alex Trebek Forum for Dialogue
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
All data produced in the present study are available upon reasonable request to the authors